STOCK TITAN

DaVita Statement on Government's Kidney Care Choices (KCC) Model Updates

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
DaVita (DVA) announced that the Center for Medicare and Medicaid Innovation (CMMI) has extended its Kidney Care Choices (KCC) Model for an additional year. The company, a leading kidney care provider, has expanded its value-based care arrangements from 11 Kidney Contracting Entities (KCEs) in 2022 to 22 KCEs currently. Recent reports show these arrangements have improved patient outcomes, including increased transplantation rates, more optimal dialysis access placement, and higher home dialysis adoption. DaVita serves approximately 282,000 patients across 3,173 outpatient dialysis centers globally, with 2,661 centers in the United States and 512 centers in 13 other countries as of March 31, 2025.
DaVita (DVA) ha annunciato che il Center for Medicare and Medicaid Innovation (CMMI) ha prorogato per un altro anno il suo modello Kidney Care Choices (KCC). L'azienda, leader nella cura dei reni, ha ampliato i suoi accordi di assistenza basata sul valore, passando da 11 Kidney Contracting Entities (KCE) nel 2022 a 22 KCE attualmente. Rapporti recenti evidenziano che questi accordi hanno migliorato i risultati per i pazienti, includendo un aumento dei trapianti, un posizionamento più ottimale degli accessi per dialisi e una maggiore adozione della dialisi domiciliare. DaVita assiste circa 282.000 pazienti in 3.173 centri di dialisi ambulatoriali nel mondo, di cui 2.661 negli Stati Uniti e 512 in 13 altri paesi, dati aggiornati al 31 marzo 2025.
DaVita (DVA) anunció que el Center for Medicare and Medicaid Innovation (CMMI) ha extendido por un año más su modelo Kidney Care Choices (KCC). La compañía, líder en el cuidado renal, ha ampliado sus acuerdos de atención basada en el valor de 11 Kidney Contracting Entities (KCE) en 2022 a 22 KCE actualmente. Informes recientes muestran que estos acuerdos han mejorado los resultados para los pacientes, incluyendo un aumento en las tasas de trasplante, una colocación más óptima de accesos para diálisis y una mayor adopción de la diálisis en el hogar. DaVita atiende aproximadamente a 282,000 pacientes en 3,173 centros de diálisis ambulatorios a nivel mundial, con 2,661 centros en Estados Unidos y 512 en 13 otros países, al 31 de marzo de 2025.
DaVita(DVA)는 Medicare 및 Medicaid 혁신 센터(CMMI)가 신장 관리 선택(KCC) 모델을 추가로 1년 연장했다고 발표했습니다. 이 회사는 신장 관리 분야의 선두주자로, 2022년 11개의 신장 계약 기관(KCE)에서 현재 22개의 KCE로 가치 기반 치료 계약을 확대했습니다. 최근 보고서에 따르면 이러한 계약은 이식률 증가, 최적의 투석 접근법 배치, 가정 투석 채택률 상승 등 환자 결과를 개선한 것으로 나타났습니다. DaVita는 2025년 3월 31일 기준 전 세계 3,173개의 외래 투석 센터에서 약 282,000명의 환자를 돌보고 있으며, 이 중 2,661개 센터는 미국에, 512개 센터는 13개국에 위치해 있습니다.
DaVita (DVA) a annoncé que le Center for Medicare and Medicaid Innovation (CMMI) a prolongé d'une année supplémentaire son modèle Kidney Care Choices (KCC). L'entreprise, leader dans les soins rénaux, a étendu ses accords de soins basés sur la valeur, passant de 11 Kidney Contracting Entities (KCE) en 2022 à 22 KCE actuellement. Des rapports récents montrent que ces accords ont amélioré les résultats des patients, notamment une augmentation des taux de transplantation, un meilleur positionnement des accès à la dialyse et une adoption accrue de la dialyse à domicile. DaVita dessert environ 282 000 patients dans 3 173 centres de dialyse ambulatoires à travers le monde, dont 2 661 aux États-Unis et 512 dans 13 autres pays, au 31 mars 2025.
DaVita (DVA) gab bekannt, dass das Center for Medicare and Medicaid Innovation (CMMI) sein Kidney Care Choices (KCC) Modell um ein weiteres Jahr verlängert hat. Das Unternehmen, ein führender Anbieter von Nierenversorgung, hat seine wertorientierten Versorgungsvereinbarungen von 11 Kidney Contracting Entities (KCEs) im Jahr 2022 auf aktuell 22 KCEs ausgeweitet. Aktuelle Berichte zeigen, dass diese Vereinbarungen die Patientenergebnisse verbessert haben, einschließlich höherer Transplantationsraten, besserer Platzierung von Dialysezugängen und höherer Akzeptanz der Heimdialyse. DaVita betreut weltweit etwa 282.000 Patienten in 3.173 ambulanten Dialysezentren, davon 2.661 in den USA und 512 in 13 weiteren Ländern, Stand 31. März 2025.
Positive
  • Extension of the Kidney Care Choices Model indicates program success and government support
  • Doubled value-based care arrangements from 11 to 22 Kidney Contracting Entities
  • Improved patient outcomes including increased transplantation and home dialysis rates
  • Large established presence with 3,173 outpatient dialysis centers serving 282,000 patients globally
Negative
  • None.

Insights

CMMI's KCC Model extension benefits DaVita's value-based kidney care strategy, supporting continued growth of their 22 care entities showing improved patient outcomes.

The one-year extension of the Kidney Care Choices Model by the Center for Medicare and Medicaid Innovation represents a significant vote of confidence in the value-based care approach DaVita has pioneered. This extension directly impacts DaVita's revenue stability and growth trajectory, as Medicare reimbursements constitute a substantial portion of the company's income stream.

The press release highlights DaVita's remarkable expansion from 11 to 22 Kidney Contracting Entities (KCEs) since 2022, demonstrating successful execution of their value-based care strategy. This 100% growth in participating entities indicates strong provider buy-in and validates DaVita's integrated care model.

Most compelling are the clinical outcome improvements cited: increased transplantation rates, more patients dialyzing with optimal access, and higher home dialysis utilization. These metrics directly correlate with reduced hospitalizations and lower total cost of care – precisely what CMMI evaluates when determining program continuation.

The extension provides DaVita additional runway to demonstrate cost savings, which typically manifest more substantially in years 3-5 of value-based programs as care coordination mechanisms mature. DaVita's two-decade experience in this space positions them advantageously compared to newer entrants, allowing them to optimize the economic benefits of the model extension while continuing to scale their KCE network.

DENVER, May 30, 2025 /PRNewswire/ -- DaVita, a comprehensive kidney care company, issued the following statement in response to updates this week from the Center for Medicare and Medicaid Innovation (CMMI) related to its Kidney Care Choices (KCC) Model. It can be attributed to Misha Palecek, chief transformation officer for DaVita.

"As a dedicated participant in the government's value-based care initiative and a pioneer in this field for the last twenty years, we applaud CMMI's decision to extend the Kidney Care Choices (KCC) Model for an additional year. We believe the investments made by CMMI and participants alike will result in long-term savings in the upcoming years. The program's emphasis on comprehensive, collaborative care and patient engagement is driving encouraging health outcomes. DaVita is committed to establishing a new standard for kidney care through integrated care systems alongside our nephrology partners."

Together with participating nephrologists, DaVita launched 11 value-based care arrangements in 2022 and has since doubled that footprint to 22 Kidney Contracting Entities (KCEs). A recent report demonstrates that these value-based care arrangements result in increased transplantation, more patients dialyzing with an optimal access in place, and more patients dialyzing at home.

To learn more about DaVita Integrated Kidney Care programs, visit DaVita.com/Innovation.

About DaVita Inc.
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for 25 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of March 31, 2025, DaVita served approximately 282,000 patients at 3,173 outpatient dialysis centers, of which 2,661 centers were located in the United States and 512 centers were located in 13 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, helped improve health access and worked collaboratively to propel the kidney care community to adopt a higher quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

Media Contact

Newsroom@davita.com

Cision View original content:https://www.prnewswire.com/news-releases/davita-statement-on-governments-kidney-care-choices-kcc-model-updates-302469731.html

SOURCE DaVita

FAQ

What is the Kidney Care Choices (KCC) Model extension announced by DaVita (DVA)?

CMMI has extended the Kidney Care Choices Model for an additional year, supporting DaVita's value-based care initiatives in kidney care.

How many Kidney Contracting Entities (KCEs) does DaVita currently operate?

DaVita has expanded from 11 KCEs in 2022 to 22 Kidney Contracting Entities currently.

What improvements has DaVita reported in their value-based care arrangements?

DaVita reported increased transplantation rates, more patients dialyzing with optimal access, and more patients dialyzing at home.

How many dialysis centers does DaVita operate as of March 2025?

DaVita operates 3,173 outpatient dialysis centers, with 2,661 in the United States and 512 centers across 13 other countries.

How many patients does DaVita serve globally?

As of March 31, 2025, DaVita served approximately 282,000 patients globally.
Davita Inc

NYSE:DVA

DVA Rankings

DVA Latest News

DVA Stock Data

10.47B
38.12M
48.62%
49.83%
5.69%
Medical Care Facilities
Services-misc Health & Allied Services, Nec
Link
United States
DENVER